Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Impedimed Limited ( (AU:IPD) ) has shared an update.
ImpediMed Limited reported a record revenue of A$3.6 million for the first quarter of FY26, despite challenges such as a stronger Australian dollar and delays in hospital approvals. The company is expanding its market presence with over 600 SOZO units installed in leading US hospitals and new system agreements providing access to over 700 hospitals. The launch of SOZO Pro, the only FDA-cleared BIS device for patients with cardiac implantable devices, is expected to drive scalable growth. Despite a decrease in Total Contracted Value compared to the previous quarter, the company saw a 9% revenue increase and maintained a low churn rate, indicating strong market demand and customer retention.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the digital health industry, focusing on providing solutions for Breast Cancer Related Lymphoedema (BCRL), heart failure, and body composition. The company leverages FDA clearances and a robust digital health platform to address growing patient needs, particularly in cancer survivorship and weight management.
Average Trading Volume: 1,763,700
Technical Sentiment Signal: Sell
Current Market Cap: A$101.8M
For an in-depth examination of IPD stock, go to TipRanks’ Overview page.